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Objectives:  To evaluate  patient  selection,  safety,  feasibility,  and  midterm  results  of  percutaneous  left  atrial
appendage (LAA)  occlusion.
Background:  Oral  anticoagulants  (OAC)  are  the  gold  standard  for stroke  prevention  in  most  patients  with
atrial  ﬁbrillation  (AF).  As the  LAA  is  the  main  source  of  AF-related  thrombi,  LAA  occlusion  might  reduce  the
thromboembolic  (TE)  risk.  Recently,  LAA  closure  was  implemented  in  the  European  Society  of  Cardiology
guidelines  for  the  management  of AF.
Methods:  This  retrospective  single  center  study  examined  all  LAA  percutaneous  closures  (September
2003–September  2011).
Results:  Twenty-ﬁve  patients  were  included  in  the  study;  median  age  at closure  was  73  years  (minimum
maximum  range  49–85  years),  68%  men.  Median  CHA2DS2-VASc  score  and  HAS-BLED  score  were  5 (IQR
4–6) and  4 (IQR  4–5),  respectively.  Most  frequent  reason  for  LAA  closure  was  intracranial  hemorrhage
during  OAC  treatment  (52%).  Successful  device  implantation  was  achieved  in  96%.  During  a follow-up  of
60.6 patient  years,  the  TE stroke  event  rate was  4.95 per  100  patient  years,  versus  an  expected  rate  of  8.78
and 2.90  without  and  with  OAC,  respectively.  No  peripheral  embolism  occurred.  Major  procedure-related
adverse  events  occurred  in two  patients.
Conclusions:  Percutaneous  closure  of  the  LAA  is feasible  and  safe.  Intracranial  hemorrhage  was  the  most
important indication  for  LAA  closure.  A low  number  of TE  stroke  events  occurred  during  follow-up.  LAA
closure  might  be  a good  alternative  in  patients  with  a  ﬁrm  contraindication  for OAC.
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Atrial ﬁbrillation (AF) is a common arrhythmia with prevalence
n Western countries from ≤0.5% at 50 years to ≥10% at 80 years
1,2]. In Asian countries the prevalence of AF in the elderly is lower,
specially in Japan where it is estimated at 3% [3]. AF increases the
isk of thromboembolic (TE) stroke, heart failure, and death [1]. The
atest European Society of Cardiology (ESC) guidelines on the man-
gement of AF recommend the use of the CHA2DS2-VASc score to
ssess the annual risk of TE stroke. With a score ≥ 2, oral anticoag-
lation (OAC) is recommended; with a score ≥ 1 (except for female
atients with gender alone as a single risk factor), OAC should be
onsidered [4]. The ESC guidelines recommended an international
ormalized ratio (INR) 2.0–3.0, but it is suspected that in Asian
opulations the optimal INR is slightly lower [5]. The HAS-BLED
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scoring system has been proposed to assess the annual risk of major
bleeding [4,6]. A HAS-BLED score ≥ 3 indicates ‘high risk,’ with a
marked increase in the major bleeding rates, irrespective of the use
of antithrombotic drugs [7].
However, the use of OACs has some limitations. First, although
indicated, OAC are actually only prescribed in less than one half of
patients with nonvalvular AF [8,9]. Second, because the difﬁculty
of proper dosing, vitamin K antagonist (VKA) monitoring requires
frequent venous blood sampling, and it has been shown that one
third of the time the INR is spent outside the therapeutic range
[10]. Finally, novel oral anticoagulant drugs (NOAC) do not require
dose adjustment on the basis of coagulation tests, appear to have
a greater net clinical beneﬁt compared to VKA, but have still a
substantial risk for bleeding [11].
The left atrial appendage (LAA) – a long, tubular, trabeculated,
and often multi-lobed structure – is the vestige of the primitive
atrium [12]. In patients with nonvalvular AF, approximately 90%
of thrombi arise from the LAA [13]. The LAA can be obliterated
surgically or percutaneously. The successful closure rate of surgi-
cal suture ligation or staple exclusion of the LAA is low, ranging
vier Ltd. All rights reserved.
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rom 40% to 66% [14–16]. More recently a technique of surgical
picardial LAA clipping has been developed, with promising short-
erm results toward safe, atraumatic, and durable exclusion of the
AA [17]. The PLAATO LAA Occlusion System® (Ev3 Endovascular,
lymouth, MN,  USA) was the ﬁrst approved percutaneous device for
AA occlusion, but although it had good 5-year study results [18],
he device was discontinued in 2007. To date there are 3 devices
n the market for percutaneous LAA occlusion. The WATCHMAN®
AA Closure Technology (Atritech, Plymouth, MN,  USA) is the only
evice that has a proven non-inferiority to OAC by a primary
omposite endpoint of stroke, cardiovascular death, and systemic
mbolism [19]. The AMPLATZERTM Cardiac Plug (AGA Medical Cor-
oration, Golden Valley, MN,  USA) does not need temporary OAC
fter implantation to allow for device endothelialization [20]. And
he LARIAT® Suture Delivery Device (Sentre HEART, Redwood City,
A, USA) is a device that closes the LAA epicardially with a pre-tied,
eﬂon coated, braided polyester suture loop [21].
We  wanted to review the records of all our patients who under-
ent percutaneous LAA closure. We  were interested in the patient
election, safety, feasibility, and mid-term results of this technique.
aterials and methods
tudy population
All patients who received a percutaneous LAA occlusion at
he University Hospitals Leuven in Belgium between September
003 and September 2011 were retrospectively studied. They had
 diagnosis of paroxysmal or persistent non-valvular AF with a
HA2DS2-VASc score ≥ 2 and a (relative) contra-indication for OAC,
r experienced a TE stroke during treatment with OAC.
The CHADS2 [22], CHA2DS2-VASc [23], and HAS-BLED [6] scores
ere calculated for all patients. The TE stroke risk associated with
he calculated CHA2DS2-VASc score of our population was esti-
ated by the data on stroke risk of a recent large cohort study
n a non-anticoagulated Danish population [24]. A theoretical TE
troke risk reduction of 67% was applied to estimate the expected TE
troke risk during OAC treatment [25]. The bleeding risk associated
ith the calculated HAS-BLED score was based on data from Friberg
t al. [7]. The institutional review board approved this retrospective
ingle center study.
evice and implanting procedure
The PLAATO LAA Occlusion System® was used in our institution
rom September 2003 until February 2006. The device consists of a
elf-expanding nitinol cage, covered with expanded polytetraﬂuo-
oethylene. Three rows of anchors along the struts help stabilize
he occluder in the appendage [26]. The AMPLATZERTM Cardiac
lug was used for all LAA occlusions from April 2010 onward. It
s constructed from a nitinol mesh and consists of a lobe and a disk
onnected by a short central waist. The diameter of the disc is a bit
arger than the lobe to assure good ﬁxation [20].
Transesophageal echocardiography (TEE) was  performed the
ay before the procedure to rule out LAA thrombus. Each procedure
as performed under general anesthesia by femoral vein approach
nd transseptal puncture under ﬂuoroscopic and TEE guidance.
ive thousand units of heparin were administered intravenously.
he activated clotting time was kept >250 s during the proce-
ure. Chest radiography and transthoracic echocardiography or
EE were performed at day 1 post-implantation, clinical follow-up
ith TEE was arranged at 6 months. All PLAATO patients were pre-
cribed aspirin, 160 mg  bid for 6 months and afterward 160 mg  qd
ndeﬁnitely, and clopidogrel, 75 mg  qd for 6 months after the pro-
edure. The AMPLATZER population was prescribed aspirin, 160 mgiology 62 (2013) 44–49 45
qd for 6 months and afterward 80 mg  qd indeﬁnitely, and clopido-
grel, 75 mg  qd for 3 months after the procedure.
Feasibility and safety
Feasibility of the percutaneous procedure was  assessed.
Safety was  deﬁned as procedure-related adverse events, and late
adverse events. The major procedure-related adverse events were
deﬁned as occurrence of procedure-related stroke, serious pericar-
dial effusion requiring drainage, major bleeding requiring ≥2 units
of packed red blood cells or surgery, and device embolization. Minor
procedure-related adverse events were deﬁned as air embolism
with transient ST-elevation, inguinal hematoma, and minor peri-
cardial effusion. Late adverse events, such as major bleeding related
to antiplatelet therapy, were also assessed.
Mid-term outcome
The event-free survival, deﬁned as absence of TE stroke or
transient ischemic attack, was assessed as the primary outcome
parameter. Peripheral embolism, death, hemorrhagic stroke, and
persistent need for OAC were also evaluated.
Statistical analysis
Continuous variables are reported as mean ± SD,  and in
case of no normal distribution, as median and interquartile or
minimum–maximum range. For proportions, numbers and per-
centages are used. Kaplan–Meier event-free survival curves, and
box plots are drawn. Statistical analysis was performed using SPSS®
(version 19, SPSS, Chicago, IL, USA).
Results
Patient demographics and baseline characteristics
Detailed results are listed in Table 1. Twenty-ﬁve patients
were treated percutaneously, with a median age of 73 years
(minimum–maximum range 49–85 years, interquartile range
70–78 years), 68% were men. There was one patient referred after
a stroke, despite previous surgical closure of the LAA by running
sutures. The median CHA2DS2-VASc score was 5 (interquartile
range 4–6), leading to an expected TE stroke rate of 8.78 and 2.90
per 100 patient years without and with OAC, respectively. The most
frequently occurring CHA2DS2-VASc characteristic was hyperten-
sion (76%), followed by stroke and vascular disease (both 60%). The
median CHADS2 score was 3 (interquartile range 2–4). The median
HAS-BLED score was  4 (interquartile range 4–5), leading to an esti-
mated mean bleeding risk during OAC treatment of 5.48 per 100
patient years. The HAS-BLED score was  ≥3 in 92%. The median
number of (relative) contraindications for OAC treatment in the
studied population was 1 (interquartile range 1–2), with intracra-
nial hemorrhage during previous OAC treatment (52%) as the most
frequent.
Feasibility and safety of device implantation
The PLAATO LAA Occlusion System® was  implanted in 10
patients (40%), the others received an AMPLATZERTM Cardiac Plug.
Successful device implantation was achieved in 96%; in 4 patients
(16%) a second, larger device was needed to secure optimal device
stability. One PLAATO LAA Occlusion System® implantation failed
because of unfavorable LAA anatomy. The mean LAA oriﬁce diam-
eter and median implant size were 19.1 ± 5.5 mm and 26 mm
(interquartile range 22–29 mm),  respectively. The median ﬂuo-
roscopy time was 26 min  (interquartile range 17–33 min). In all
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Table 1
Patient demographics and baseline characteristics.
Percutaneous intervention,
N = 25
PLAATO,
N = 10
AMPLATZERTM Cardiac Plug,
N = 15
Age, median (range), y 73 (49–85) 72 (65–79) 75 (49–85)
Male  68.0% (17) 90.0% (9) 46.7% (7)
CHADS2 score, median (IQR) 3 (2–4) 4 (3–4) 3 (2–3)
0  0.0% (0) 0.0% (0) 0.0% (0)
1  16.0% (4) 10.0% (1) 20.0% (3)
2  16.0% (4) 10.0% (1) 20.0% (3)
3  36.0% (9) 20.0% (2) 46.7% (7)
4  32.0% (8) 60.0% (6) 13.3% (2)
5  0.0% (0) 0.0% (0) 0.0% (0)
6  0.0% (0) 0.0% (0) 0.0% (0)
CHA2DS2-VASc score, median (IQR) 5 (4–6) 5.5 (5–6) 5 (3.5–5)
0  0.0% (0) 0.0% (0) 0.0% (0)
1  0.0% (0) 0.0% (0) 0.0% (0)
2  8.0% (2) 0.0% (0) 13.3% (2)
3  12.0% (3) 10.0% (1) 13.3% (2)
4  16.0% (4) 10.0% (1) 20.0% (3)
5  36.0% (9) 30.0% (3) 40.0% (6)
6  24.0% (6) 50.0% (5) 6.7% (1)
7  4.0% (1) 0.0% (0) 6.7% (1)
8  0.0% (0) 0.0% (0) 0.0% (0)
9  0.0% (0) 0.0% (0) 0.0% (0)
Congestive heart failure/left ventricle dysfunction 24.0% (6) 30.0% (3) 20.0% (3)
Hypertension 76.0% (19) 90.0% (9) 66.7% (10)
Age  ≥ 75 (doubled) 44.0% (11) 30.0% (3) 53.3% (8)
Diabetes 20.0% (5) 20.0% (2) 20.0% (3)
Stroke (doubled) 60.0% (15) 80.0% (8) 46.7% (7)
Vascular disease 60.0% (15) 80.0% (8) 46.7% (7)
Age  65–74 y 48.0% (12) 70.0% (7) 33.3% (5)
Sex  category (female) 32.0% (8) 10.0% (1) 46.7% (7)
HAS-BLED score, median (IQR) 4 (4–5) 4.5 (4–5) 4 (4–5)
Hypertension 76.0% (19) 90.0% (9) 66.7% (10)
Abnormal renal or liver function 16.0% (4) 20.0% (2) 13.3% (2)
Abnormal renal and liver function (doubled) 4.0% (1) 0.0% (0) 6.7% (1)
Stroke 60.0% (15) 80.0% (8) 46.7% (7)
Bleeding history or predisposition 84.0% (21) 70.0% (7) 93.3% (14)
Labile INR 36.0% (9) 20.0% (2) 46.7% (7)
Elderly (>65 y) 88.0% (22) 90.0% (9) 86.7% (13)
Drugs/alcohol concomitantly 56.0% (14) 80.0% (8) 40.0% (6)
Drugs/alcohol concomitantly (doubled) 8.0% (2) 0.0% (0) 13.3% (2)
Contra-indication OAC
TIA/stroke during OAC treatment 12.0% (3) 20.0% (2) 6.7% (1)
Intracranial hemorrhage 52.0% (13) 70.0% (7) 40.0% (6)
Cerebral AVM 4.0% (1) 0.0% (0) 6.7% (1)
Peptic ulcer 16.0% (4) 30.0% (3) 6.7% (1)
Gastrointestinal hemorrhage 16.0% (4) 20.0% (2) 13.3% (2)
Chronic liver disease 12.0% (3) 10.0% (1) 13.3% (2)
Intolerance to OAC therapy 24.0% (6) 10.0% (1) 33.3% (5)
Gait  instability 20.0% (5) 20% (2) 20.0% (3)
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atients in whom TEE was performed during follow-up (N = 15), an
ffective closure (≤2-mm residual LAA leak by TEE color Doppler
valuation) was found, except for one patient with a 3-mm jet.
Detailed safety results are listed in Table 2. There were
rocedural-related adverse events recorded in 7 patients (29.2%).
wo major procedure-related adverse events occurred: one device
mbolized in the aorta leading to percutaneous snare recuperation,
nd in one a possible procedure-related stroke was noted. No late
evice-related complications occurred during follow-up. The only
ate adverse event recorded, was a subdural hemorrhage 6.5 years
fter a PLAATO procedure in a patient with a HAS-BLED score of 5.
his patient never stopped taking clopidogrel at the discretion of
is cardiologist.id-term outcome
The PLAATO LAA Occlusion System® implant failure was
xcluded from further follow-up. The patients who were restartedk; OAC, oral anticoagulants; AVM, arteriovenous malformation.
on OAC were included in the follow-up until the day of the reintro-
duction of OAC. Detailed results are listed in Table 3.
During a follow-up of 60.6 patient years, TE strokes were
recorded in 3 patients (12.5%), recalculated to 4.95 events per 100
patient years. There were 2 TE strokes (a lacunar plus cerebellar
infarction and an occipital infarction, 79 and 973 days after device
implantation, respectively) in the PLAATO cohort, and 1 pontine
stroke 3 days after the AMPLATZERTM Cardiac Plug implantation. At
the time of the TE event, all patients received the correct antithrom-
botic therapy, as speciﬁed in the Materials and methods section.
No thrombus was  visualized on the devices after a TE event. A
Kaplan–Meier analysis of time to TE-related stroke was performed
(Fig. 1). Box plots are drawn for the expected TE stroke risk (Fig. 2).
No peripheral embolism was  recorded during the follow-up period.
Death occurred in 4 patients (16.7%); all were categorized as
unrelated to the device or procedure and were associated with
patient comorbidities (dolichoectasia of the basilar artery with
thrombogenic material, interstitial lung disease, exact cause of
death was unknown for a patient with a liver transplant, and one
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Table  2
Safety.
Percutaneous intervention,
N = 24
PLAATO,
N = 9
AMPLATZERTM Cardiac Plug,
N = 15
Major procedure-related adverse events
Procedural stroke 4.2% (1) 0.0% (0) 6.7% (1)
Per  procedural device embolization 4.2% (1) 11.1% (1) 0.0% (0)
Serious pericardial effusion/cardiac
Tamponade 0.0% (0) 0.0% (0) 0.0% (0)
Major bleeding 0.0% (0) 0.0% (0) 0.0% (0)
Minor procedure-related adverse events
Inguinal hematoma 12.5% (3) 22.2% (2) 6.7% (1)
Air  embolism with transient ST-
Elevation 8.3% (2) 11.1% (1) 6.7% (1)
Minor  pericardial effusion 4.2% (1) 0.0% (0) 6.7% (1)
Late  adverse events
Major bleeding 4.2% (1) 11.1% (1) 0.0% (0)
Table 3
Mid-term outcome.
Percutaneous intervention,
N = 24
PLAATO,
N = 9
AMPLATZERTM Cardiac Plug,
N = 15
Follow-up, mean ± SD, d 1763 ± 880 416 ± 213
Follow-up, patient years 60.6
TE stroke/TIA 12.5% (3) 22.2% (2) 6.7% (1)
AF-associated TE stroke/TIA 8.3% (2) 11.1% (1) 6.7% (1)
Hemorrhagic stroke 0.0% (0) 0.0% (0) 0.0% (0)
Death 12.5% (3) 33.3% (3) 0.0% (0)
Persistent need for OAC 12.5% (3) 11.1% (1) 13.3% (2)
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aD, standard deviation; TE, thromboembolic; TIA, transient ischemic attack; AF, atrith severe dementia). No hemorrhagic strokes were recorded.
n 3 percutaneously treated patients (12.5%), OAC treatment was
estarted. Phenprocoumon was prescribed in one patient after a TE
troke. The other 2 were started on dabigatran in a medical need
ig. 1. Kaplan–Meier analysis of time to thromboembolic (TE) stroke. The table
epicts the time after the index procedure, the actual number of patients at risk
t  each year-end, the number of events, and the percentage of patients free of TE
troke. The blue line is the Kaplan–Meier estimate of probability of remaining free
f  TE stroke, with vertical lines = censored patients. (For interpretation of the refer-
nces to color in this ﬁgure legend, the reader is referred to the web  version of the
rticle.)illation; OAC, oral anticoagulants.
program. The indications for dabigatran were a patent foramen
ovale and prothrombin mutation in a patient aged 49 years; the
other patient experienced a non-ST elevation myocardial infarction
despite only discrete coronary artery disease (a differential diag-
nosis of coronary artery disease, coronary spasms, and coronary
embolism was  made).
Fig. 2. Box plot of thromboembolic (TE) stroke risk. This box plot depicts the theo-
retical TE stroke risk in our population with and without oral anticoagulants (OAC),
based upon the calculated CHA2DS2-VASc score, and the corresponding estimated
TE stroke risk of each patient (as previously explained). Red line = observed TE stroke
event rate per 100 patient years. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of the article.)
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Percutaneous LAA obliteration is safe and feasible; efﬁciency is
uggested to be comparable with the use of OAC.
fﬁciency of LAA occlusion
We  recorded 4.95 TE strokes per 100 patient years. The recorded
troke rate was much lower than the estimated mean TE stroke rate
f 8.78 per 100 patient years in a non-OAC setting. It is higher than
he estimated mean TE stroke rate of 2.90 per 100 patient years
n an OAC setting, but our patients were deemed unsuitable for
AC. To calculate the risk of a TE event, we used the data of a non-
nticoagulated Danish population [24], and applied a theoretical TE
troke risk reduction of 67% [25] to estimate the TE stroke risk with-
ut and with OAC, rather than adapting the TE stroke risk values
rom the original CHA(2)DS2-(VASc) studies [22,27]. We  believed
hat these recent data in a large cohort give a more accurate pre-
iction of the TE stroke rate. We  also preferred the CHA2DS2-VASc
core in our risk assessment, as this newer scoring system is more
ccurate in predicting the TE stroke risk compared to CHADS2 score
4,7,24]. The theoretical TE stroke rate with aspirin treatment was
ot calculated, because aspirin has limited and no signiﬁcant effect
n TE stroke rates (−19%) [25].
When looking more closely to the three recorded TE strokes,
wo appeared to be AF-related. In one patient who  sustained a
iscrete pontine stroke, 3 days after AMPLATZERTM Cardiac Plug
mplantation, a “late” periprocedural embolism into the posterior
irculation could not be excluded. There were no hypertensive
pisodes, neither periprocedural transient ST-elevations, nor neu-
ologic signs directly post-device implantation recorded. Therapy
ith OAC was not restarted in this patient; to date no new ischemic
vents were documented. It could be hypothesized that a throm-
us was formed on the device shortly after implantation during the
ngoing endothelialization process of the device. However, there
as no thrombus visualized on the device, and the AMPLATZERTM
ardiac Plug does not need temporary OAC after implantation [20].
 second patient sustained a bilateral occipital infarction 973 days
fter implantation of a PLAATO LAA Occlusion System® which could
e AF or aortic atherosclerotic related. He was switched to OAC
fterward. After critical review of a third case, it was concluded
hat this patient sustained a non-AF-related TE stroke. This patient,
ith dolichoectasia of the basilar artery containing thrombogenic
aterial, sustained a lacunar infarction of the right thalamus and
n infarction in the right cerebellar hemisphere, and subsequently
eveloped an asystolic cardiac arrest. Indeed, LAA occlusion will
ot inﬂuence all the possible sources of thromboemboli. Plaques in
he aorta, carotid or vertebral artery, or venous thrombi via right-
o-left-shunting are other possible origins of thromboemboli [28].
easibility and safety of device implantation
Percutaneous LAA obliteration is feasible. We  achieved a suc-
essful device implantation in 96% of patients. This is comparable
o the 97.3% in the PLAATO 5-year follow-up study [18], the 91% in
he PROTECT AF study [19], and the 95% in the CAP Registry [29].
Percutaneous LAA obliteration is a relatively safe technique
ith complications mostly related to the operator’s experience.
t is not easy to compare the safety results with previous expe-
iences in LAA closure, because of differences in the deﬁnition of
ajor adverse events. Compared to the 6.3% major adverse events
ithin one month of the index procedure in the PLAATO Inter-
ational Multi-Center Feasibility Trial (deﬁned as: new major or
inor stroke, cardiac or neurological death, myocardial infarction,
r requirement for cardiovascular surgery related to the PLAATO
rocedure) [26], we experienced 4.2% events (one new stroke).iology 62 (2013) 44–49
Compared to the 7.7% in the PROTECT AF study, and the 3.7%
safety events in the CAP Registry (deﬁned as: pericardial effu-
sion/tamponade, procedure-related stroke, device embolization,
and excessive bleeding events requiring transfusion) [29], we expe-
rienced 12.6% events. Compared to the 7.0% major complications
up to 24 h after implantation in the AMPLATZERTM Initial European
Experience study (deﬁned as: death, stroke, systemic embolism,
device embolization, pericardial bleeding requiring an interven-
tion, or other major bleeding) [20], we recorded 4.2% complications.
Patient selection
The recent updated ESC guidelines give a class IIb, level B recom-
mendation for percutaneous LAA obliteration: it may  be considered
in patients with a high stroke risk and contraindications for long-
term OAC. They do note that the need for lifelong aspirin treatment
after interventional LAA occlusion, and the signiﬁcant associated
bleeding risk, may  pose a problem [4]. The net clinical beneﬁt of
LAA closure is positive, as assessed by a recent post hoc analysis of
the PROTECT-AF trial and the CAP registry [30].
There is still an important barrier to the prescription of OAC
among physicians, certainly amongst the elderly AF patients. The
risk of falls, and previous bleeding are also reported to be impor-
tant contributors to these phenomena [31]. Although a recently
published prospective study demonstrated that a high risk of falls is
not related to an increased risk of major bleeds [32], all our patients
had another valid reason to avoid OAC. Indeed, the most prevalent
reason for LAA closure in our series was  a history of severe (intracra-
nial) hemorrhage on OAC. As 92% of our patients had a HAS-BLED
score ≥ 3, they were at high risk for major bleeding rates, irrespec-
tive of the use of antiplatelet therapy or OAC [7]. These selection
criteria were comparable to the PLAATO 5-year follow-up study
[18]. With the recent availability of the NOAC, where the risk for
an intracranial hemorrhage is signiﬁcantly lower [33–35], the indi-
cation for LAA closure devices could narrow in the future. To date
there are still controversies if NOAC should be used as ﬁrst-line
agents in AF [36,37]. However, after critical retrospective analysis
of our cases, eleven have a ﬁrm contraindication for any type of
OAC. Almost all other patients had a fear for continuation of VKA
after major bleeding incidents and refused further treatment with
VKA, and it is hard to assess retrospectively if they would be con-
vinced to take NOAC. It is essential to make a proper risk–beneﬁt
assessment toward OAC, and exclude only those patients who have
a ﬁrm contraindication for VKA or NOAC. Finally, our patients were
at high risk for a TE event. When comparing the TE risk stratiﬁca-
tion of our percutaneous study population to these of the PLAATO
5-year follow-up study [18], and the PROTECT AF study [19], a
CHADS2 score of ≥3 was  present in 68%, 55.4%, and 32%, respec-
tively. Remarkably, we  had no CHADS2 scores ≥ 5 in our population,
compared to 9.4%, and 5% in the other studies, respectively. The
CHA2DS2-VASc scores were not available for comparison.
The LARIAT® Suture Delivery Device is based on the obliteration
of the LAA by an epicardial snare that is inserted subxiphoidally. The
experience with this device is limited to one efﬁcacy and safety
study where the patients with a CHADS2 score of ≥2 who could
tolerate OAC were recommended to continue these drugs [21].
Therefore it is of no interest in our patient population.
Study limitations
This study was a retrospective single center study with a rela-
tively small sample size and a follow-up ranging from a few months
to multiple years, precluding any reliable comparison between
devices in terms of safety and efﬁcacy. At the time of inclusion
of the patients in the LAA closure program, NOAC were not yet
approved for use in AF, which could have inﬂuenced the LAA closure
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opulation. Patients with major difﬁculties to keep the INR within
herapeutic range, or those that experience major side effects of
KA, could possibly be switched to NOAC. All limitations of retro-
pective studies apply, especially the presence of a selection bias.
onclusion
We  examined the data of percutaneous LAA closure in patients
ith AF. It seems to be a feasible and safe technique. Intracranial
emorrhage was the most important reason for LAA closure. A low
umber of TE stroke events occurred during follow-up. We  believe
hat LAA closure in selected patients with a ﬁrm contraindication
or OAC might offer beneﬁt.
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